Abstract
Granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) are cytokines of particular interest in oncology from the perspective of neutropenia management (Mehta et al., 2015 [1]) and also as indirect activators of tumor-associated macrophages and modifiers of tumor microenvironment. Associated with poor breast cancer survival and unfavorable hormone receptor status (Wintrob et al., 2017 [2]), insulin may also influence hematopoiesis, thus interfering with colony stimulating factor production. Although G-CSF has been linked to exacerbating insulin resistance (Ordelheide et al., 2016 [3]), thus far no study linked insulin treatment and hematopoietic cytokines production. Additionally, IL-7 is the primary driver of T and B cell differentiation, maturation, and response (Corfe and Paige, 2012 [4]) and its elevated levels have been associated with poor prognosis in breast cancer.The data presented here is among the first to show a relationship between pre-existing use of injectable insulin in women diagnosed with breast cancer and type 2 diabetes mellitus, hematopoietic cytokine profiles at time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis evaluating the relationship between G-CSF, GM-CSF, and IL-7 stratified by insulin use, controls, as well as by estrogen and progesterone receptor status is also provided.
Highlights
Insulin use, hormone receptor status and hematopoietic cytokines' circulation in women with diabetes mellitus and breast cancer
interleukin- 7 (IL-7) is the primary driver of T and B cell differentiation, maturation, and response (Corfe and Paige, 2012 [4]) and its elevated levels have been associated with poor prognosis in breast cancer
A Pearson correlation analysis evaluating the relationship between Granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), and IL-7 stratified by insulin use, controls, as well as by estrogen and progesterone receptor status is provided. & 2017 Published by Elsevier Inc
Summary
Tables Tumor registry query was followed by vital status ascertainment, and medical records review Luminexs-based quantitation of hematopoietic cytokines (granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, and interleukin- 7) from plasma samples was conducted. United States, Buffalo, NY - 42° 53' 50.3592"N; 78° 52' 2.658"W This dataset represents the observed relationship between injectable insulin use, hormone receptor status, circulating hematopoietic cytokines at breast cancer diagnosis, and outcomes. Reported data represents the observed association between use of injectable insulin preceding breast cancer and the hematopoietic cytokine profiles at the time of cancer diagnosis in women with diabetes mellitus (Table 1). Correlation with each of the studied hematopoietic cytokine is presented, the details regarding these biomarkers’ determination from plasma, association with cancer outcomes and use of injectable insulin is reported in a distinct dataset [6]. Evaluation of hematopoietic cytokine profile association with injectable insulin use and BC outcomes was carried out under two protocols approved by both Roswell Park Cancer Institute (EDR154409 and NHR009010) and the State University of New York at Buffalo (PHP0840409E).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
